Credit Suisse AG increased its position in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 26.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 878,824 shares of the biopharmaceutical company’s stock after buying an additional 183,440 shares during the period. Credit Suisse AG owned about 3.89% of Esperion Therapeutics worth $31,030,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Quantbot Technologies LP bought a new position in Esperion Therapeutics during the first quarter worth about $158,000. Keybank National Association OH acquired a new stake in shares of Esperion Therapeutics during the fourth quarter worth approximately $159,000. C WorldWide Group Holding A S acquired a new stake in shares of Esperion Therapeutics during the first quarter worth approximately $162,000. Elkfork Partners LLC acquired a new stake in shares of Esperion Therapeutics during the fourth quarter worth approximately $169,000. Finally, Princeton Alpha Management LP acquired a new stake in shares of Esperion Therapeutics during the first quarter worth approximately $205,000. Institutional investors own 81.45% of the company’s stock.
Esperion Therapeutics, Inc. (NASDAQ:ESPR) traded down 1.626% during midday trading on Monday, reaching $43.619. 127,590 shares of the company’s stock traded hands. Esperion Therapeutics, Inc. has a one year low of $9.40 and a one year high of $48.21. The stock’s 50 day moving average price is $34.90 and its 200-day moving average price is $26.60. The stock’s market cap is $985.35 million.
Esperion Therapeutics (NASDAQ:ESPR) last released its quarterly earnings results on Monday, May 1st. The biopharmaceutical company reported ($1.80) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.44) by $0.36. During the same quarter last year, the company posted ($0.65) earnings per share. Equities analysts predict that Esperion Therapeutics, Inc. will post ($6.78) earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: “Credit Suisse AG Boosts Position in Esperion Therapeutics, Inc. (ESPR)” was posted by BBNS and is owned by of BBNS. If you are reading this news story on another domain, it was stolen and republished in violation of U.S. & international trademark & copyright law. The original version of this news story can be read at https://baseballnewssource.com/markets/credit-suisse-ag-boosts-position-in-esperion-therapeutics-inc-espr/1095436.html.
A number of brokerages have commented on ESPR. BidaskClub upgraded shares of Esperion Therapeutics from a “hold” rating to a “buy” rating in a research note on Sunday. Citigroup Inc. restated a “buy” rating on shares of Esperion Therapeutics in a research note on Thursday. Deutsche Bank AG began coverage on shares of Esperion Therapeutics in a research note on Friday. They set a “buy” rating and a $48.00 price target for the company. J P Morgan Chase & Co boosted their price target on shares of Esperion Therapeutics from $22.00 to $50.00 in a research note on Tuesday, March 21st. Finally, Zacks Investment Research lowered shares of Esperion Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, May 1st. Eight analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Esperion Therapeutics has an average rating of “Buy” and a consensus target price of $31.93.
About Esperion Therapeutics
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with our FREE daily email newsletter.